In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen

Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis

(2016) Julliana Ribeiro Alves Santos et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya

(2013) A.-C. L. Meyer et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast

(2012) Tatsuya Shibata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin B

(2011) Maryam Iman et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Consensus multi-locus sequence typing scheme forCryptococcus neoformansandCryptococcus gattii

(2009) Wieland Meyer et al.   MEDICAL MYCOLOGY

In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine

(2008) J. Mitsuyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY